Tiziana Life Sciences, Ltd. (TLSA) Tuesday reported encouraging results from an open-label study evaluating nasal foralumab for the treatment of non-active secondary progressive multiple sclerosis (na-SPMS).
Results from the study showed that all patients treated with nasal foralumab experienced stabilization of their Expanded Disability Status Scale (EDSS) scores; Fatigue improved in six out of ten patients; TSPO-PET imaging showed significant reductions in microglial activation at six months; and no serious or severe treatment-related adverse events were reported.
Tiziana has initiated a Phase 2 study to further assess the efficacy and safety of nasal foralumab in a larger cohort of patients with na-SPMS. Top line data from the study is expected at the end of the year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.